Your browser doesn't support javascript.
loading
Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN-CTO registry.
Kalra, Sanjog; Doshi, Darshan; Sapontis, James; Kosmidou, Ioanna; Kirtane, Ajay J; Moses, Jeffrey W; Riley, Robert F; Jones, Philip; Nicholson, William J; Salisbury, Adam C; Lombardi, William L; McCabe, James M; Pershad, Ashish; Hirai, Taishi; Hakemi, Emad; Russo, Juan J; Prasad, Megha; Ahmad, Yousif; Hatem, Raja; Gkargkoulas, Fotis; Spertus, John A; Wyman, R Michael; Jaffer, Farouc; Spaedy, Anthony; Cook, Stephen; Marso, Steven P; Nugent, Karen; Federici, Robert; Yeh, Robert W; Leon, Martin B; Stone, Gregg W; Ali, Ziad A; Parikh, Manish A; Maehara, Akiko; Cohen, David J; Batres, Candido; Grantham, J Aaron; Karmpaliotis, Dimitri.
  • Kalra S; Department of Medicine, Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania.
  • Doshi D; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Sapontis J; MonashHeart, Monash University, Melbourne, Australia.
  • Kosmidou I; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.
  • Kirtane AJ; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
  • Moses JW; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.
  • Riley RF; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
  • Jones P; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.
  • Nicholson WJ; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
  • Salisbury AC; St. Francis Heart Center, St. Francis Hospital, Roslyn, New York.
  • Lombardi WL; Heart and Vascular Institute, The Christ Hospital, Cincinnati, Ohio.
  • McCabe JM; St. Luke's Mid America Heart Institute, Kansas City, Missouri.
  • Pershad A; Department of Medicine, Wellspan York Hospital, York, Pennsylvania.
  • Hirai T; St. Luke's Mid America Heart Institute, Kansas City, Missouri.
  • Hakemi E; Department of Medicine, University of Missouri, Kansas City, Missouri.
  • Russo JJ; Department of Medicine, University of Washington Medical Center, Seattle, Washington.
  • Prasad M; Department of Medicine, University of Washington Medical Center, Seattle, Washington.
  • Ahmad Y; Department of Medicine, Banner University Medical Center, Phoenix, Arizona.
  • Hatem R; Department of Medicine, University of Missouri, Kansas City, Missouri.
  • Gkargkoulas F; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.
  • Spertus JA; Ottawa Heart Institute, Ottawa, Ontario, Canada.
  • Wyman RM; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.
  • Jaffer F; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.
  • Spaedy A; Department of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Cook S; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.
  • Marso SP; Department of Medicine, University of Missouri, Kansas City, Missouri.
  • Nugent K; Torrance Memorial Medical Center, Torrance, California.
  • Federici R; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Yeh RW; Boone County Hospital, Columbia, Missouri.
  • Leon MB; Peacehealth Sacred Heart Medical Center, Springfield, Oregon.
  • Stone GW; Research Medical Center, Kansas City, Missouri.
  • Ali ZA; St. Luke's Mid America Heart Institute, Kansas City, Missouri.
  • Parikh MA; Presbyterian Health System, Albuquerque, New Mexico.
  • Maehara A; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Cohen DJ; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.
  • Batres C; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
  • Grantham JA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
  • Karmpaliotis D; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Catheter Cardiovasc Interv ; 97(6): 1162-1173, 2021 05 01.
Article en En | MEDLINE | ID: mdl-32876381
ABSTRACT

OBJECTIVES:

We sought to assess in-hospital and long-term outcomes of retrograde compared with antegrade-only percutaneous coronary intervention for chronic total occlusion (CTO PCI).

BACKGROUND:

Procedural and clinical outcomes following retrograde compared with antegrade-only CTO PCI remain unknown.

METHODS:

Using the core-lab adjudicated OPEN-CTO registry, we compared the outcomes of retrograde to antegrade-only CTO PCI. Primary endpoints included were in-hospital major adverse cardiac and cerebrovascular events (MACCE) (all-cause death, stroke, myocardial infarction [MI], emergency cardiac surgery, or clinically significant perforation) and MACCE at 1-year (all-cause death, MI, stroke, target lesion revascularization, or target vessel reocclusion).

RESULTS:

Among 885 single CTO procedures from the OPEN-CTO registry, 454 were retrograde and 431 were antegrade-only. Lesion complexity was higher (J-CTO score 2.7 vs. 1.9; p < .001) and technical success lower (82.4 vs. 94.2%; p < .001) in retrograde compared with antegrade-only procedures. All-cause death was higher in the retrograde group in-hospital (2 vs. 0%; p = .003), but not at 1-year (4.9 vs. 3.3%; p = .29). Compared with antegrade-only procedures, in-hospital MACCE rates (composite of all-cause death, stroke, MI, emergency cardiac surgery, and clinically significant perforation) were higher in the retrograde group (10.8 vs. 3.3%; p < .001) and at 1-year (19.5 vs. 13.9%; p = .03). In sensitivity analyses landmarked at discharge, there was no difference in MACCE rates at 1 year following retrograde versus antegrade-only CTO PCI. Improvements in Seattle Angina Questionnaire Quality of Life scores at 1-year were similar between the retrograde and antegrade-only groups (29.9 vs 30.4; p = .58).

CONCLUSIONS:

In the OPEN-CTO registry, retrograde CTO procedures were associated with higher rates of in-hospital MACCE compared with antegrade-only; however, post-discharge outcomes, including quality of life improvements, were similar between technical modalities.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oclusión Coronaria / Intervención Coronaria Percutánea Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oclusión Coronaria / Intervención Coronaria Percutánea Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article